CN113303476A - Application of rubidium salt and rubidium salt solution in preparation of product with prolonged service life and/or anti-aging - Google Patents
Application of rubidium salt and rubidium salt solution in preparation of product with prolonged service life and/or anti-aging Download PDFInfo
- Publication number
- CN113303476A CN113303476A CN202110444333.3A CN202110444333A CN113303476A CN 113303476 A CN113303476 A CN 113303476A CN 202110444333 A CN202110444333 A CN 202110444333A CN 113303476 A CN113303476 A CN 113303476A
- Authority
- CN
- China
- Prior art keywords
- rubidium
- rubidium salt
- life
- aging
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003297 rubidium Chemical class 0.000 title claims abstract description 37
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000012266 salt solution Substances 0.000 title claims abstract description 10
- 230000002035 prolonged effect Effects 0.000 title description 6
- 239000007788 liquid Substances 0.000 claims description 6
- -1 organic acid anions Chemical class 0.000 claims description 5
- 229910001419 rubidium ion Inorganic materials 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- NCCSSGKUIKYAJD-UHFFFAOYSA-N rubidium(1+) Chemical compound [Rb+] NCCSSGKUIKYAJD-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000018553 tannin Nutrition 0.000 claims description 2
- 229920001864 tannin Polymers 0.000 claims description 2
- 239000001648 tannin Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 241000244203 Caenorhabditis elegans Species 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 27
- 101100447050 Caenorhabditis elegans daf-16 gene Proteins 0.000 abstract description 17
- 230000032683 aging Effects 0.000 abstract description 10
- 230000008642 heat stress Effects 0.000 abstract description 10
- 230000005855 radiation Effects 0.000 abstract description 9
- 230000035558 fertility Effects 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 7
- 230000035882 stress Effects 0.000 abstract description 7
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 abstract description 6
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 abstract description 6
- 230000037361 pathway Effects 0.000 abstract description 6
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 241000244206 Nematoda Species 0.000 description 79
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 52
- 239000002609 medium Substances 0.000 description 25
- 229940102127 rubidium chloride Drugs 0.000 description 25
- 239000000047 product Substances 0.000 description 16
- RTHYXYOJKHGZJT-UHFFFAOYSA-N rubidium nitrate Inorganic materials [Rb+].[O-][N+]([O-])=O RTHYXYOJKHGZJT-UHFFFAOYSA-N 0.000 description 11
- KHAUBYTYGDOYRU-IRXASZMISA-N trospectomycin Chemical compound CN[C@H]([C@H]1O2)[C@@H](O)[C@@H](NC)[C@H](O)[C@H]1O[C@H]1[C@]2(O)C(=O)C[C@@H](CCCC)O1 KHAUBYTYGDOYRU-IRXASZMISA-N 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 7
- FOGKDYADEBOSPL-UHFFFAOYSA-M rubidium(1+);acetate Chemical compound [Rb+].CC([O-])=O FOGKDYADEBOSPL-UHFFFAOYSA-M 0.000 description 7
- 229910000344 rubidium sulfate Inorganic materials 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001360 synchronised effect Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000011177 media preparation Methods 0.000 description 5
- 230000005937 nuclear translocation Effects 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- GANPIEKBSASAOC-UHFFFAOYSA-L rubidium(1+);sulfate Chemical compound [Rb+].[Rb+].[O-]S([O-])(=O)=O GANPIEKBSASAOC-UHFFFAOYSA-L 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- WPFGFHJALYCVMO-UHFFFAOYSA-L rubidium carbonate Chemical compound [Rb+].[Rb+].[O-]C([O-])=O WPFGFHJALYCVMO-UHFFFAOYSA-L 0.000 description 3
- 229910000026 rubidium carbonate Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 101100321927 Caenorhabditis elegans aak-2 gene Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000006353 environmental stress Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 159000000005 rubidium salts Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 101150076104 EAT2 gene Proteins 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000010632 Transcription Factor Activity Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000010196 hermaphroditism Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention discloses the use of a rubidium salt and a rubidium salt solution for the preparation of a product with an extended life and/or an anti-ageing property. The invention confirms the correlation between rubidium salt and aging through a phenotype experiment, the rubidium salt can activate DAF-16 through an AMPK pathway to prolong the life of the caenorhabditis elegans, enhance the capabilities of resisting heat stress, ultraviolet radiation and oxidation stress, does not influence the normal vital signs and the fertility of the caenorhabditis elegans, and has no toxic or side effect on the safety of the caenorhabditis elegans. Therefore, the product has good anti-aging effect and can be applied to the preparation of products with anti-aging and life prolonging effects.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to application of a rubidium salt and a rubidium salt solution in preparation of a product with prolonged service life and/or anti-aging performance.
Background
Aging is an inevitable part of life process and can be delayed. Aging is characterized by a decreased ability to respond to stress, an increased imbalance in homeostasis, and an increased risk of aging-related diseases, including cancer and heart disease. Aging is defined as the "process of gradual deterioration of physiological function, age-related loss of vitality and increased vulnerability". Aging is a major factor that causes a large increase in the incidence of chronic diseases such as intellectual disabilities, cardiovascular diseases, stroke, chronic respiratory diseases, cancer, and the like. These diseases are therefore also referred to as geriatric diseases, which pose a great burden on the healthcare system.
Lithium, sodium, potassium, rubidium and cesium belong to elements of a first main group, simple substances of the elements are active in chemical property, ions of the elements are stable in chemical property, and sodium and potassium ions are the material basis for functional operation of various systems of a human body, particularly a nervous system. The living system is specially provided with a sodium plasma channel, a potassium plasma channel and a chlorine plasma channel to maintain the operation of the living system.
Rubidium salts are relatively poorly studied in the health field because of the difficulty of extraction. In 2019, Zhengxiaooyak et al reported (Frontiers In Pharmacology, 2019, (10): 1-12.) that RbCl had anti-osteoporosis effect, and the mechanism thereof was not clear. The first main group elements are deeply researched to expand the application of the first main group elements in the fields of biological medicine and health, and the first main group elements have important value and significance.
Disclosure of Invention
The object of the present invention is to overcome the drawbacks or drawbacks of the prior art and to provide the use of a rubidium salt and a rubidium salt solution for the preparation of products with extended life and/or anti-ageing properties. The invention confirms the correlation between rubidium salt and aging through a phenotype experiment, the rubidium salt can activate DAF-16 through an AMPK pathway to prolong the life of the caenorhabditis elegans, enhance the capabilities of resisting heat stress, ultraviolet radiation and oxidation stress, does not influence the normal vital signs and the fertility of the caenorhabditis elegans, and has no toxic or side effect on the safety of the caenorhabditis elegans. Therefore, the product has good anti-aging effect and can be applied to the preparation of products with anti-aging and life prolonging effects.
In order to achieve the above purpose of the present invention, the present invention provides the following technical solutions:
use of a rubidium salt and a rubidium salt solution for the preparation of a product with extended life and/or anti-ageing properties.
Caenorhabditis elegans (Caenorhabditis elegans) is a major model organism for anti-aging studies. Based on the model, more than 800 genes are found to be related to the regulation of the longevity of caenorhabditis elegans, and compounds with anti-aging effect (such as metformin and rapamycin) are found.
Caenorhabditis elegans, which are hermaphrodite adults 1mm long, possess 959 cells, and are also a postmitotic model, with mitotic activity occurring only in the gonads. This simplified function is useful for exploring cell degeneration associated with aging. Three days later, one generation can be passed, so that faster genetic studies can be performed. Caenorhabditis elegans has larger propagules and can be cultured at different temperatures, so that quantitative experiments on senescence can be performed and an automatic molecular target screening system can be created.
The inventor of the invention confirms the correlation between rubidium salt and aging through a phenotype experiment, the rubidium salt can activate DAF-16 through an AMPK pathway to prolong the life of the caenorhabditis elegans, enhance the capabilities of resisting heat stress, ultraviolet radiation and oxidation stress, does not influence the normal vital signs and the fertility of the caenorhabditis elegans, and has no toxic or side effect on the safety of the caenorhabditis elegans. Therefore, the product has good anti-aging effect and can be applied to the preparation of products with anti-aging and life prolonging effects.
Specifically, the rubidium salt is anti-aging and longevity-enhancing by at least:
(a) the ultraviolet radiation resistance is enhanced;
(b) enhancing the anti-oxidative stress capability;
(c) enhancing the ability to resist heat stress;
(d) the service life is prolonged;
(e) activation of DAF-16 by the AMPK pathway enhances resistance and prolongs life.
It should be appreciated that the solvent of the rubidium salt solution is water.
The life prolonging referred to in the present invention means to prolong the maximum length of the life of the body or delay the death time.
Preferably, the rubidium salt is rubidium ion Rb+Salts with stable inorganic or organic acid anions.
More preferably, the inorganic acid anion is chloride ion Cl-Sulfate radical SO4 2-Nitrate radical NO3 -Carbonate CO3 2-Or acetate CH3COO-One or more of them.
More preferably, the organic acid radical anion is one or more of citrate, gallate and tannin.
Preferably, the drug concentration of rubidium salt in the longevity-extended and/or anti-aging product is between 1 μmol and 100 mmol.
Preferably, the extended life and/or anti-aging product includes a rubidium salt or a rubidium salt solution, and further includes one or more pharmaceutically acceptable excipients.
More preferably, the adjuvant is a diluent, a filler, a binder, a wetting agent, an absorption enhancer, a surfactant, a lubricant, or a stabilizer.
Preferably, the longevity-extending and/or anti-aging product is a food, health care product, feed or additive thereof.
It is to be understood that the food, health product, feed or additive thereof may further contain ingredients commonly used in the art, which are appropriately selected by those skilled in the art depending on the formulation form or the purpose of use, and may be used together with other materials.
Preferably, the life-prolonging and/or anti-aging product is formulated in the form of tablets, granules, capsules, powders, liquids or jellies.
Compared with the prior art, the invention has the following advantages and effects:
the invention confirms the correlation between rubidium salt and aging through a phenotype experiment, the rubidium salt can activate DAF-16 through an AMPK pathway to prolong the life of the caenorhabditis elegans, enhance the capabilities of resisting heat stress, ultraviolet radiation and oxidation stress, does not influence the normal vital signs and the fertility of the caenorhabditis elegans, and has no toxic or side effect on the safety of the caenorhabditis elegans. Therefore, the product has good anti-aging effect and can be applied to the preparation of products with anti-aging and life prolonging effects.
Drawings
FIG. 1 Effect of rubidium chloride on longevity of wild-type C.elegans;
FIG. 2 effect of rubidium chloride on longevity of CF1038 C.elegans;
FIG. 3 effect of rubidium chloride on RB754 caenorhabditis elegans longevity;
FIG. 4 effect of rubidium chloride on the longevity of DA1113 C.elegans;
FIG. 5 effect of rubidium chloride on the longevity of DR1572 C.elegans;
FIG. 6 rubidium sulfate has no effect on the fertility of caenorhabditis elegans;
FIG. 7 mean life effect of rubidium acetate on caenorhabditis elegans heat stress (35 ℃);
FIG. 8 protective effect of rubidium acetate on caenorhabditis elegans heat stress (35 ℃);
FIG. 9 mean life effect of rubidium nitrate on caenorhabditis elegans ultraviolet radiation;
FIG. 10 protective effect of rubidium nitrate on the ultraviolet radiation of C.elegans;
FIG. 11 protective effect of rubidium carbonate on oxidative stress of caenorhabditis elegans;
FIG. 12 Effect of rubidium chloride on nuclear translocation of TJ356 C.elegans daf 16;
FIG. 13 rubidium chloride activates nuclear translocation of TJ356 caenorhabditis elegans daf 16.
Detailed Description
The present invention will be further explained with reference to the following examples and drawings, but the examples are not intended to limit the present invention in any manner. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Unless otherwise indicated, reagents and materials used in the present invention are commercially available.
Example 1 application of rubidium chloride to prolongation of caenorhabditis elegans Life
(1) Preparing strains: escherichia coli (Escherichia coli) OP50 was inoculated into LB liquid medium (4g peptone, 4g NaCl, 2g yeast extract, 4mL pH 8.01 MTirs-HCl buffer, added with ultrapure water to 400mL, autoclaved), shake-cultured overnight, and placed in a refrigerator at 4 ℃ for further use.
(2) Preparation of NGM culture medium: a500 mL Erlenmeyer flask was charged with 1.2g of NaCl, 6.8g of agar, 1g of peptone, and ultrapure water to 400mL, and autoclaved. After the solution cooled to about 60 deg.C, 400. mu.l of 1MCaCl was added to the clean bench 2400 μ l of 5mg/mL cholesterol, 400 μ l of 1MMgSO4, 10mL of 1M KHPO4The buffer solution is evenly stirred, poured into a culture dish (35mm), kept stand for solidification and then placed in a refrigerator at 4 ℃ for later use.
(3) Plate preparation: a200 μ lOP50 bacterial suspension was sucked by a pipette gun on a super clean bench into the center of the NGM medium, and the bacterial suspension was allowed to stand after being spread out by slight shaking (in the case of setting the experimental group, a rubidium salt aqueous solution was mixed into the bacterial suspension to make the final rubidium salt concentration 100 μ M and 10 mM). And after the bacterial liquid is dried, placing the bacterial liquid in a refrigerator at 4 ℃ for later use.
(4) Nematode transfer: picking the nematodes on the NGM culture medium by using a platinum wire under a stereoscopic microscope, and culturing in a constant temperature incubator at 20 ℃.
(5) And (3) nematode passage: cutting a small piece of NGM culture medium which can be passaged by a knife on a clean bench, putting the small piece of NGM culture medium on a fresh NGM culture medium with the front face downward, slightly compacting the small piece of NGM culture medium, and then putting the small piece of NGM culture medium in a constant temperature incubator for culture at 20 ℃.
(6) Nematode synchronization: the anti-aging activity of N2 wild-type C.elegans (WT) on rubidium salts was studied. In order to obtain nematodes in the same growth stage, the nematodes are subjected to a synchronization treatment. Newly-passaged nematodes are grown to the adult stage by about 2 days of culture. The surface of the NGM medium was washed with 1mL of ultrapure water on a clean bench, transferred to a 5mL centrifuge tube, and washed twice. Rinse solution (0.5mL of 0.5M sodium hydroxide, 1mL of 4% sodium hypochlorite, 5mL of ultrapure water) was added. Vortex for 10s and then stand for 2min, repeat for about 5 times until the nematode is seen to be substantially dissolved by naked eyes. Centrifuge at 800rpm for 3 min. The supernatant was discarded, 5mL of ultrapure water was added, and the mixture was centrifuged at 800rpm for 3 min. The supernatant was discarded and the pellet was blown up and dropped onto fresh NGM medium. After the liquid is evaporated, the mixture is put into a constant temperature incubator for culture at 20 ℃.
(7) Life test: life tests were carried out using WT wild type, CF1038(daf-16(mu86) I), DA1113(eat-2(ad1113) II), DR1572(daf-2(e1368) III), RB754(aak-2(ok524) X) and other lines. The synchronized nematodes were placed individually on NGM medium (blank control (noted WT), 100. mu.M rubidium chloride, and 10mM rubidium chloride), which was noted as Day 0 (Day 0), and cultured in an incubator at 20 ℃ for 3 days. Adult nematodes were transferred to corresponding groups of fresh NGM medium (3 media per group, 80 nematodes per media). Thereafter, the survival and death of nematodes was observed and counted every other day, and the nematodes were transferred to fresh NGM medium until all of the nematodes died (when the number of nematodes surviving on the medium decreased to a certain number, the nematodes of the same group could be pooled on the same medium). Criteria for determining death are: the caenorhabditis elegans has no reaction to strong light or a knocking dish, muscles of hypopharynx of a high power mirror do not move, and finally the head of the caenorhabditis elegans is knocked by a picking needle, and the caenorhabditis elegans can be judged to be dead if the head still has no reaction.
(8) The experimental results are as follows: as shown in FIG. 1 and Table 1, the average life span of wild-type nematodes (P < 0.0001) was significantly extended by adding rubidium chloride (100. mu.M and 10mM) to the nematode diet. Compared with a control group, the average service life of 100 mu M rubidium chloride can be improved by 12 percent, and the maximum service life can be prolonged by 6 percent. Compared with a control group, the average service life of 10mM rubidium chloride can be improved by 18 percent, and the maximum service life can be prolonged by 6 percent. The average life span of the nematode increases with the increasing concentration of the rubidium chloride, and has certain concentration dependence. The rubidium chloride can prolong the life of wild caenorhabditis elegans and has the function of anti-aging.
As shown in FIGS. 2-5 and tables 2-5, rubidium chloride was unable to prolong nematode longevity in CF1038(DAF-16(mu86) I) and RB754(aak-2(ok524) X) strains, indicating that rubidium chloride might activate DAF-16 via the AMPK pathway to prolong nematode longevity.
TABLE 1 Effect of different concentrations of rubidium chloride on the longevity of wild-type nematodes
Represents P <0.001 compared to WT group.
TABLE 2 Effect of different concentrations of rubidium chloride on the longevity of CF1038 nematodes
Represents P <0.001 compared to WT group.
TABLE 3 Effect of different concentrations of rubidium chloride on RB754 nematode longevity
Represents P <0.05 compared to WT group.
TABLE 4 Effect of different concentrations of rubidium chloride on the longevity of DA1113 nematodes
Represents P <0.001 compared to WT group.
###Representing P <0.001 compared to the DA1113 group.
TABLE 5 Effect of different concentrations of rubidium chloride on the longevity of DR1572 nematodes
Represents P <0.001 compared to WT group.
#Representing P <0.05 compared to group DR 1572.
Example 2 rubidium sulfate has no effect on the fertility of caenorhabditis elegans
Nematode species preparation, NGM medium preparation, plating, nematode transfer, nematode passage, and nematode synchronization were performed as described in example 1. The synchronized nematodes were placed individually on NGM medium (WT, 100. mu. MRb)2SO4，10mM Rb2SO4) At this time, Day 0 (Day 0) was recorded, and the cells were incubated at 20 ℃ for 3 days in an incubator. Adult nematodes were transferred to the corresponding fresh NGM medium (4 media per group, 1 nematode per media). Culturing at 20 ℃ in a constant-temperature incubator, counting the number of eggs laid by the nematodes once a day, and transferring the nematodes to a fresh NGM medium until the nematodes stop laying eggs.
The experimental results are as follows: in caenorhabditis elegans, a decrease in nematode fertility is often observed at the same time as the longevity is extended. The change in the number of adult nematode eggs laid after feeding rubidium sulfate (100. mu.M and 10mM) was explored. As shown in FIG. 6, there was no significant change in the number of eggs laid by C.elegans after feeding rubidium sulfate (100. mu.M and 10mM) compared to the control group, indicating that rubidium sulfate had no effect on the fertility of nematodes.
Example 3 rubidium acetate enhances caenorhabditis elegans heat stress resistance
The strain preparation, NGM medium preparation, plating, nematode transfer, nematode passage and nematode synchronization were performed as described in example 1. The synchronized nematodes were placed in NGM medium (WT, 100. mu. MCH) separately3COORb，10mM CH3COORb), which was recorded as Day 0 (Day 0), was cultured in an incubator at 20 ℃ for 3 days. Adult nematodes were transferred to the corresponding groups of fresh NGM medium (3 per group, 50 nematodes per medium) and continued to culture up to Day 6 (Day 6). The culture medium was transferred to a 35 ℃ incubator and observed and counted every hour for survival and death of nematodes.
The experimental results are as follows: while the compounds extend the life of the nematode, they often also enhance the nematode's resistance to various environmental stresses. The variation in nematode tolerance to the high temperature (35 ℃) environment was explored following feeding rubidium acetate (100. mu.M and 10 mM). As shown in fig. 7-8 and table 6, the average lifetime of 100 μ M rubidium acetate was improved by 14% and the maximum lifetime was improved by 7% (P <0.001) compared to the control group; the average life of 10mM rubidium salt can be improved by 17% (extending from 8.5 +/-0.5 h to 10.3 +/-0.7 h), and the maximum life is improved by 7% (P is less than 0.001). Indicating that the rubidium acetate can obviously enhance the resistance of the nematode to acute heat stress.
TABLE 6 protection of nematode heat stress (35 ℃) by rubidium acetate at different concentrations
P < 0.0001 in comparison to WT group.
Example 4 rubidium nitrate enhances the resistance to ultraviolet radiation by caenorhabditis elegans
Preparation of the Strain NGM medium preparation, plating, nematode transfer, nematode passage, and nematode synchronization were performed as described in example 1. UV irradiation was also one of the environmental stresses, and the synchronized nematodes were placed individually on NGM medium (blank control (WT), 100. mu. MRbNO)3，10mM RbNO3) At this time, Day 0 (Day 0) was recorded, and the cells were incubated at 20 ℃ for 3 days in an incubator. Adult nematodes were transferred to corresponding groups of fresh NGM medium (3 medium per group, 80 nematodes per medium) and continued to be cultured up to Day 6 (Day 6). The nematodes were transferred to unboard blank NGM medium and subjected to UV irradiation (300 mj/cm)2). After irradiation, nematodes were transferred to fresh NGM medium and observed and counted as viable and dead once a day.
The experimental results are as follows: as shown in fig. 9-10 and table 7, in three independent replicates, the average life of 100 μ M rubidium nitrate was increased by 4% and the maximum life was increased by 11% compared to the control group after feeding rubidium nitrate (100 μ M and 10 mM); the average life of 10mM rubidium salt can be improved by 9%, and the maximum life is improved by 11% (P < 0.05). Indicating that the rubidium nitrate can enhance the resistance of the caenorhabditis elegans to ultraviolet irradiation.
TABLE 7 protective Effect of rubidium nitrate of different concentrations on nematode UV radiation
Represents P <0.05 compared to WT group.
Example 5 rubidium carbonate enhances oxidative stress resistance of caenorhabditis elegans
The strain preparation, NGM medium preparation, plating, nematode transfer, nematode passage and nematode synchronization were performed as described in example 1. The synchronized nematodes were placed on NGM medium (blank control group (WT group), 10mM Rb2CO3) At this time, Day 0 (Day 0) was recorded, and the cells were incubated at 20 ℃ for 3 days in an incubator. Adult nematodes were transferred to the corresponding fresh NGM medium (50 nematodes per medium) and continued to be cultured until Day 6 (Day 6). Transferring the nematodes to a solution containing 400. mu.M jugloneAnd (4) continuously culturing the nematode on the NGM culture medium for 24 hours at the temperature of 20 ℃ in a constant-temperature incubator, observing and counting the survival and death conditions of the nematode, and repeating the experiment for three times.
The experimental results are as follows: as shown in FIG. 11, the average survival rate of 10mM rubidium nitrate after feeding rubidium nitrate (10mM) was 16.2% higher (P <0.05) than that of the control group in three independent replicates. Indicating that the rubidium nitrate can enhance the resistance of caenorhabditis elegans to oxidative stress.
Example 6 rubidium chloride extension of caenorhabditis elegans longevity by nuclear translocation of DAF16
The strain preparation, NGM medium preparation, plating, nematode transfer, nematode passage and nematode synchronization were performed as described in example 1. Translocation of DAF-16 from the cytoplasm to the nucleus is a critical step in its transcription factor activity. Activation of DAF16 is associated with stress resistance. The effect of rubidium salt on nuclear translocation of daf16 was observed using transgenic TJ356 nematodes (zIs356 IV [ daf-16:: GFP + pRF6 ]). The synchronized nematodes were placed on NGM medium (blank control (denoted TJ356), 10mM RBCl (denoted TJ356/10mM RBCl)), now denoted Day 0 (Day 0), and incubated in a thermostated incubator at 20 ℃ for 3 days. 2-3 adult nematodes were picked and placed on a glass slide with agar pad (5% agar solution was dropped in the center of the glass slide, flattened with another glass slide, and the upper glass slide was removed at the time of use), covered with a cover glass, and DAF-16 expression (20X, 488nm) of the nematodes was observed under a confocal laser microscope, and more than 10 nematodes were observed per group, and the experiment was repeated three times.
The experimental results are as follows: as shown in FIGS. 12 to 13, the number of nuclear translocation nematodes increased by 63.84% (P <0.001) in the case of feeding rubidium chloride (10mM) compared with the control group. Indicating that rubidium chloride can activate DAF16 to enhance nematode resistance and prolong life span.
It should be finally noted that the above examples are only intended to illustrate the technical solutions of the present invention, and not to limit the scope of the present invention, and that other variations and modifications based on the above description and thought may be made by those skilled in the art, and that all embodiments need not be exhaustive. Any modification, equivalent replacement, and improvement made within the spirit and principle of the present invention should be included in the protection scope of the claims of the present invention.
Claims (9)
1. Use of a rubidium salt and a rubidium salt solution for the preparation of a product with extended life and/or anti-ageing properties.
2. The use according to claim 1, wherein said rubidium salt is rubidium ion Rb+Salts with stable inorganic or organic acid anions.
3. Use according to claim 2, characterized in that the mineral acid anion is chloride Cl-Sulfate radical SO4 2-Nitrate radical NO3 -Carbonate CO3 2-Or acetate CH3COO-One or more of them.
4. The use of claim 2, wherein the organic acid anion is one or more of citrate, gallate and tannin.
5. The use according to claim 1, wherein said pharmaceutical concentration of rubidium salt in said extended life and/or anti-aging product is between 1 μmol and 100 mmol.
6. The use according to claim 1, wherein said extended-life and/or anti-aging product comprises a rubidium salt or a rubidium salt solution, and further comprises one or more pharmaceutically acceptable adjuvants.
7. Use according to claim 1, wherein the excipient is a diluent, filler, binder, wetting agent, absorption enhancer, surfactant, lubricant or stabilizer.
8. Use according to claim 1, wherein the life-extending and/or anti-ageing product is a food, a nutraceutical, a feed or an additive thereof.
9. The use according to claim 1, wherein the life-extending and/or anti-aging product is formulated in the form of tablets, granules, capsules, powders, liquids or jellies.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110444333.3A CN113303476B (en) | 2021-04-23 | 2021-04-23 | Application of rubidium salt and rubidium salt solution in preparation of product with prolonged service life and/or anti-aging |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110444333.3A CN113303476B (en) | 2021-04-23 | 2021-04-23 | Application of rubidium salt and rubidium salt solution in preparation of product with prolonged service life and/or anti-aging |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113303476A true CN113303476A (en) | 2021-08-27 |
| CN113303476B CN113303476B (en) | 2022-10-04 |
Family
ID=77372701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110444333.3A Active CN113303476B (en) | 2021-04-23 | 2021-04-23 | Application of rubidium salt and rubidium salt solution in preparation of product with prolonged service life and/or anti-aging |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113303476B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005065695A1 (en) * | 2003-12-26 | 2005-07-21 | Giles Brian C | Method and formula for suppression of cancer, metastasis, vascularization, and pain suppression |
| US20060008908A1 (en) * | 2004-07-08 | 2006-01-12 | Giles Brian C | Method and composition for longevity assurance |
| WO2007140280A1 (en) * | 2006-05-24 | 2007-12-06 | Pharmaionix Inc. | Anti-cancer composition and method for using the same |
-
2021
- 2021-04-23 CN CN202110444333.3A patent/CN113303476B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005065695A1 (en) * | 2003-12-26 | 2005-07-21 | Giles Brian C | Method and formula for suppression of cancer, metastasis, vascularization, and pain suppression |
| US20060008908A1 (en) * | 2004-07-08 | 2006-01-12 | Giles Brian C | Method and composition for longevity assurance |
| WO2007140280A1 (en) * | 2006-05-24 | 2007-12-06 | Pharmaionix Inc. | Anti-cancer composition and method for using the same |
Non-Patent Citations (4)
| Title |
|---|
| 李卫敏等: "脑的微量元素与衰老", 《国外医学.医学地理分册》 * |
| 李莹等: "《主管护师资格考试复习精粹.2019年》", 31 July 2018, 中国协和医科大学出版社 * |
| 王继华等: "《肥育猪饲料配方设计技术》", 28 February 2013, 科学技术文献出版社 * |
| 迟永柏等: "《中医学传统保健体育运动养生》", 31 August 2017, 中医古籍出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113303476B (en) | 2022-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69532766T2 (en) | PLASMID FOR IL-2 EXPRESSION | |
| Dey et al. | Characterization of a Leishmania stage‐specific mitochondrial membrane protein that enhances the activity of cytochrome c oxidase and its role in virulence | |
| CN102131927B (en) | Adjustable type gene suicide mechanism combination thing and method | |
| CN104159609B (en) | The restructuring KHV and vaccine of disease caused by for preventing Koi herpesvirus (KHV) | |
| EP2794849B1 (en) | Method for producing high yield attenuated salmonella strains | |
| Weber et al. | Immunization of broiler chicks by in ovo injection of Eimeria tenella sporozoites, sporocysts, or oocysts | |
| EP2111234B1 (en) | Methods of releasing sporocysts from oocysts using controlled shear forces | |
| CN113303476B (en) | Application of rubidium salt and rubidium salt solution in preparation of product with prolonged service life and/or anti-aging | |
| Matinha‐Cardoso et al. | Novel protein carrier system based on cyanobacterial nano‐sized extracellular vesicles for application in fish | |
| Taheri et al. | Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivity | |
| CN111587114A (en) | Use of imidazopyrimidines for modulating the immune response in humans | |
| CN107586329B (en) | Polypeptide separated from pomfret | |
| Barros et al. | Low transformation growth factor-β1 production and collagen synthesis correlate with the lack of hepatic periportal fibrosis development in undernourished mice infected with Schistosoma mansoni | |
| Scheel et al. | Nutrition of plant-sucking Hemiptera | |
| CN110585223B (en) | Flavonoid inhibitor for resisting fish viruses and preparation method and application thereof | |
| Nadirah et al. | The Effect of Heat Stress on the Oxidative Status of Red Hybrid Tilapia (Oreochromis sp.) Infected With Streptococcus Agalactiae. | |
| CN111821464A (en) | Rabbit coccidiosis attenuated live vaccine suspending agent for drinking water immunization and preparation method thereof | |
| US20160348085A1 (en) | Recombinant l-asparaginase from zymomonas | |
| EP1721965A1 (en) | Method for the preparation and use of protozoan cultures | |
| Marietto-Gonçalves et al. | Effects of Lactobacillus probiotic, P22 bacteriophage and Salmonella typhimurium on the heterophilic burst activity of broiler chickens | |
| CN114774371B (en) | Vibrio phage and application thereof | |
| CN114574450B (en) | Ultraviolet-resistant Proteus mirabilis bacteriophage with broad cleavage spectrum, composition and kit thereof, and application of phage | |
| Astuya et al. | Production of extracts with anaesthetic activity from the culture of Heterosigma akashiwo in pilot-scale photobioreactors | |
| AU2019271310B2 (en) | Parasite vaccine | |
| Adams | Novel Methods for Controlling and Diagnosing Avian Coccidiosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |